(Bloomberg) -- GSK Plc will sell its remaining stake in Haleon Plc for £1.25 billion ($1.6 billion), completing the drugmaker’s separation from the consumer health company.Most Read from BloombergChina Attempts to End Property Crisis With Broad Rescue PackageUS Inflation Data Was Accidentally Released 30 Minutes EarlyWith a BlackRock CEO, $9 Trillion Vanguard Braces for TurbulencePutin and Xi Vow to Step Up Fight to Counter US ‘Containment’Jamie Dimon Sees ‘Lot of Inflationary Forces in Front of